A Ikido Pharma Inc. AIKI
We take great care to ensure that the data presented and summarized in this overview for AIkido Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AIKI
View all-
Vanguard Group Inc Valley Forge, PA193KShares$734,8890.0% of portfolio
-
Black Rock Inc. New York, NY72.5KShares$275,5720.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny42.9KShares$163,1180.0% of portfolio
-
Geode Capital Management, LLC Boston, MA39.2KShares$149,0700.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX37.4KShares$142,0280.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX20.5KShares$77,9000.0% of portfolio
-
State Street Corp Boston, MA20KShares$75,9460.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny18.2KShares$69,1600.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA12.1KShares$46,1240.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY4.04KShares$15,3330.0% of portfolio
Latest Institutional Activity in AIKI
Top Purchases
Top Sells
About AIKI
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Insider Transactions at AIKI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2024
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Direct |
3,482
+1.54%
|
$6,964
$2.4 P/Share
|
|
May 29
2024
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
5,000
+15.27%
|
$10,000
$2.2 P/Share
|
|
May 29
2024
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Direct |
1,158
+0.52%
|
$2,316
$2.25 P/Share
|
|
Apr 08
2024
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
8,500
+19.68%
|
$17,000
$2.99 P/Share
|
|
Apr 05
2024
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
13,500
+10.4%
|
$27,000
$2.88 P/Share
|
|
Apr 04
2024
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
3,944
+3.7%
|
$7,888
$2.62 P/Share
|
|
Apr 04
2024
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
19,000
+41.96%
|
$38,000
$2.87 P/Share
|
|
Dec 26
2023
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
5,000
+35.71%
|
$10,000
$2.6 P/Share
|
|
Dec 26
2023
|
Christopher Franklin Devall COO |
BUY
Open market or private purchase
|
Direct |
7,000
+18.9%
|
$14,000
$2.55 P/Share
|
|
Dec 21
2023
|
Kyle Michael Wool President |
BUY
Grant, award, or other acquisition
|
Direct |
630,050
+30.31%
|
$1,260,100
$2.02 P/Share
|
|
Dec 20
2023
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
70,000
+41.47%
|
$140,000
$2.0 P/Share
|
|
Dec 12
2023
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
4,000
+41.67%
|
$8,000
$2.03 P/Share
|
|
Dec 12
2023
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
4,000
+6.72%
|
$8,000
$2.0 P/Share
|
|
Nov 30
2023
|
Christopher Franklin Devall COO |
BUY
Open market or private purchase
|
Direct |
1,000
+4.16%
|
$2,000
$2.28 P/Share
|
|
Nov 28
2023
|
Christopher Franklin Devall COO |
BUY
Open market or private purchase
|
Direct |
1,000
+4.34%
|
$2,000
$2.26 P/Share
|
|
Nov 27
2023
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
1,000
+4.0%
|
$2,000
$2.2 P/Share
|
|
Nov 24
2023
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
1,481
+5.63%
|
$2,962
$2.16 P/Share
|
|
Nov 22
2023
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
1,323
+5.37%
|
$2,646
$2.09 P/Share
|
|
Nov 20
2023
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Indirect |
2,000
+8.0%
|
$4,000
$2.05 P/Share
|
|
Nov 16
2023
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Indirect |
2,500
+10.2%
|
$2,500
$1.97 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 210K shares |
|---|---|
| Grant, award, or other acquisition | 1.26M shares |